Sun Pharma signs pact with LIB Therapeutics for LDL-C drug
In short
Sun Pharma signed a pact with LIB Therapeutics to sell a drug that lowers LDL-C. The medicine, lerodalcibep, is a once-monthly treatment and is approved in the EU as Lyrokaul and in the U.S. as Lerochol.
This matters because it could expand Sun Pharma’s product line in cholesterol treatment. The reporting does not say the deal value, launch date, or target markets.
What the reporting says
Sun Pharma signed a pact with LIB Therapeutics to sell a drug for lowering LDL-C, according to the reporting. The source identifies the medicine as lerodalcibep, a once-monthly PCSK9 inhibitor approved in the EU as Lyrokaul and in the U.S. as Lerochol. It does not state the financial terms, launch timing, or where Sun Pharma will market the drug.
Why it matters
Sun Pharma signed an agreement with LIB Therapeutics to sell lerodalcibep, a once-monthly PCSK9 inhibitor used to lower LDL-C in adults with hypercholesterolaemia and mixed dyslipidaemia. The drug already has EU and U.S. approvals under different brand names. The reporting highlights a potential commercial opportunity for Sun Pharma, but the deal terms are not stated.